Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 49

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 49
---
umab for other indications, and (iv) for working capital and other general corporate purposes. See “Use of              
 Proceeds” on page S-11.                                                                                                                 |
| Nasdaq Capital Market Symbol                           |     | Our common shares are listed                                                                                                            
 on The Nasdaq Capital Market under the symbol “TLSA.”                                                                                   |
| Risk Factors                                           |     | This investment involves                                                                                                                
 a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus as well as the other information                     
 included in or incorporated by reference in this prospectus for a discussion of risks you should consider carefully before making       
 an investment decision.                                                                                                                 |

| (1) | The number of shares of                                                                                                          
 our common shares that will be outstanding after this offering is based on 116,847,732 common shares outstanding as of March 14, 
 2025, and excludes as of that date:                                                                                              |

| ● | 7,610,702                                                                                                                     
 common shares issuable upon the exercise of share options at exercise prices of between $0.50 and $3.72 per common share; and |

| ● | 4,200,000                                                                 
 common shares issuable upon the vesting of restricted stock units (RSUs). |

Unless otherwise indicated, this prospectus reflects and assumes no exercise of outstanding share options or warrants or conversion of convertible notes after March 14, 2025. Unless otherwise stated, all information contained in this prospectus reflects the assumed public offering price of $1.57 per common share, which was the closing price of our common shares on The Nasdaq Capital Market on March 14, 2025.

<div align='center'>S-5

RISK FACTORS</div>

An investment in the common shares involves a high degree of risk. Prior to making a decision about investing in these securities, you should carefully consider the specific risks, uncertainties and assumptions discussed under the heading “Risk Factors” included in our most recent Annual Report on Form 20-F, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. Our business, financial condition or results of operations could be materially adversely affected by any of these risks which cause you to lose all or part of your investment in the offered securities. Certain statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference into the prospectus supplement are forward